Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PIKing the right patient.

Literature DB >> 20538763

PIKing the right patient.

Abstract

HER2 amplification and PIK3CA mutation were validated as biomarkers for sensitivity to the single-agent phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0941, in breast cancer models. A novel expression profile was developed to identify other breast cancers sensitive to PI3K inhibitors. These expression studies highlighted feedback networks connecting TORC1, PI3K, and mitogen-activated protein kinase (MAPK) pathways, and underscored the potential for combination therapies. Copyright 2010 AACR.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20538763 DOI： 10.1158/1078-0432.CCR-10-1201

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

7 in total

1. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

Authors: Ashish A Kulkarni; Bhaskar Roy; Poornima S Rao; Gregory A Wyant; Ayaat Mahmoud; Madhumitha Ramachandran; Poulomi Sengupta; Aaron Goldman; Venkata Ramana Kotamraju; Sudipta Basu; Raghunath A Mashelkar; Erkki Ruoslahti; Daniela M Dinulescu; Shiladitya Sengupta
Journal: Cancer Res Date: 2013-10-11 Impact factor: 12.701

2. Cancer genomics: from discovery science to personalized medicine.

Authors: Lynda Chin; Jannik N Andersen; P Andrew Futreal
Journal: Nat Med Date: 2011-03 Impact factor: 53.440

3. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Authors: Antonio Jimeno; Julie E Bauman; Charles Weissman; Douglas Adkins; Ian Schnadig; Patrice Beauregard; Daniel W Bowles; Alexander Spira; Benjamin Levy; Nagashree Seetharamu; Diana Hausman; Luke Walker; Charles M Rudin; Keisuke Shirai
Journal: Oral Oncol Date: 2015-01-13 Impact factor: 5.337

7. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.

Authors: C Stengel; C W Cheung; J Quinn; K Yong; A Khwaja
Journal: Leukemia Date: 2012-03-14 Impact factor: 11.528

7 in total

PIKing the right patient.

1. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

2. Cancer genomics: from discovery science to personalized medicine.

3. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Review 4. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.

5. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.

6. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.

7. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.